BR0310062A - Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos - Google Patents

Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos

Info

Publication number
BR0310062A
BR0310062A BR0310062-6A BR0310062A BR0310062A BR 0310062 A BR0310062 A BR 0310062A BR 0310062 A BR0310062 A BR 0310062A BR 0310062 A BR0310062 A BR 0310062A
Authority
BR
Brazil
Prior art keywords
antigens
chitosan
adjuvant
compositions
release
Prior art date
Application number
BR0310062-6A
Other languages
English (en)
Inventor
Giuseppe Del Giudice
Barbara Baudner
Original Assignee
Univ Leiden
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Chiron Srl filed Critical Univ Leiden
Publication of BR0310062A publication Critical patent/BR0310062A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"VACINAS MUCOSAS COM ADJUVANTE DE QUITOSANA E/OU ANTìGENOS MENINGOCóCICOS". A invenção fornece composições imunogênicas que compreendem (a) um antígeno de sacarídeo capsular de sorogrupo C de N. meningitidis, e (b) um adjuvante de quitosana. A composição preferivelmente compreende (c) um ou mais antígenos adicionais e/ou (d) um ou mais adjuvantes adicionais. As composições são particularmente adequadas para liberação mucosa, incluindo liberação intranasal. A invenção também fornece composições imunogênicas para liberação mucosa que compreendem sacarídeos capsulares de pelo menos dois dos sorogrupos A, C, W135 e Y de N. meningitidis. Prefere-se que os sacarídeos capsulares nas composições da invenção sejam conjugados a proteína (s) transportadora (s) e/ou sejam oligossacarídeos. São particularmente preferidos antígenos conjugados de oligossacarídeo.
BR0310062-6A 2002-05-14 2003-05-14 Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos BR0310062A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38067502P 2002-05-14 2002-05-14
GBGB0302218.3A GB0302218D0 (en) 2003-01-30 2003-01-30 Vaccine formulation & Mucosal delivery
PCT/IB2003/002382 WO2003094834A2 (en) 2002-05-14 2003-05-14 Mucosal vaccines with chitosan adjuvant and meningococcal antigens

Publications (1)

Publication Number Publication Date
BR0310062A true BR0310062A (pt) 2005-02-15

Family

ID=9952172

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0310062-6A BR0310062A (pt) 2002-05-14 2003-05-14 Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
BR0407101-8A BRPI0407101A (pt) 2003-01-30 2004-01-30 Vacinas meningocócicas mucosais

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0407101-8A BRPI0407101A (pt) 2003-01-30 2004-01-30 Vacinas meningocócicas mucosais

Country Status (13)

Country Link
US (1) US8926992B2 (pt)
EP (2) EP1506008B1 (pt)
JP (4) JP4696260B2 (pt)
CN (1) CN100579580C (pt)
AU (1) AU2003233128B2 (pt)
BR (2) BR0310062A (pt)
CA (1) CA2485992C (pt)
ES (2) ES2328128T3 (pt)
GB (1) GB0302218D0 (pt)
MX (1) MXPA05007886A (pt)
NZ (1) NZ536715A (pt)
RU (2) RU2004136299A (pt)
WO (1) WO2003094834A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20060147466A1 (en) * 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1594536B1 (en) * 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Adjuvanted influenza vaccine
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
RU2378010C2 (ru) 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
PT2351578T (pt) 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2008039390A2 (en) * 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
SG174845A1 (en) 2006-09-29 2011-10-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
KR102134980B1 (ko) * 2007-04-06 2020-07-16 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CA2702871A1 (en) * 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
SI3246044T2 (sl) 2010-08-23 2024-06-28 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
ES2585328T5 (es) 2010-09-10 2022-12-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
WO2013009849A1 (en) 2011-07-11 2013-01-17 Ligocyte Pharmaceuticals, Inc. Parenteral norovirus vaccine formulations
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EP2844262B1 (en) * 2012-04-30 2018-01-10 Biothera, Inc. Beta-glucan immunotherapeutic preparation
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
EP3530285B1 (en) * 2016-10-20 2023-08-09 KM Biologics Co., Ltd. METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT
EP3522856B1 (en) * 2016-11-08 2022-03-23 Colgate-Palmolive Company Oral care compositions
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
CA3126492A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
UY39226A (es) * 2020-05-22 2021-12-31 Alberto Riveros Carlos Sistema, método y uso de un medicamento para reducir la replicación viral en las vías respiratorias

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
AU755502C (en) * 1999-03-24 2003-08-14 Secretary Of State For Defence, The Immunostimulants
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
EP1244468A2 (en) 2000-01-07 2002-10-02 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
AP1695A (en) * 2000-06-29 2006-12-17 Glaxosmithkline Biologicals Sa Multivalent vaccine composition.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0029919D0 (en) * 2000-12-07 2001-01-24 Chiron Spa Helicobacter pylori prime & boost vaccination
RO122761B1 (ro) 2001-01-23 2010-01-29 Aventis Pasteur Vaccin multivalent antimeningococic conţinând polizaharid-proteină
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002080648A2 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003028661A2 (en) 2001-10-03 2003-04-10 Chiron Corporation Adjuvanted meningococcus compositions
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
WO2003059385A2 (en) 2002-01-14 2003-07-24 Chiron Corporation Hiv vaccine and method of use
CN1643549A (zh) * 2002-03-18 2005-07-20 皇家飞利浦电子股份有限公司 有价票据的保持器以及记录其内容的方法
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US20060147466A1 (en) 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis

Also Published As

Publication number Publication date
CA2485992C (en) 2013-07-09
CA2485992A1 (en) 2003-11-20
ES2328128T3 (es) 2009-11-10
CN1767853A (zh) 2006-05-03
EP1587538A1 (en) 2005-10-26
JP4696260B2 (ja) 2011-06-08
NZ536715A (en) 2007-02-23
EP1506008A2 (en) 2005-02-16
MXPA05007886A (es) 2005-09-21
BRPI0407101A (pt) 2006-01-24
RU2349342C2 (ru) 2009-03-20
JP2012046550A (ja) 2012-03-08
JP2015061879A (ja) 2015-04-02
WO2003094834A3 (en) 2004-05-21
AU2003233128A1 (en) 2003-11-11
GB0302218D0 (en) 2003-03-05
JP2016104813A (ja) 2016-06-09
RU2004136299A (ru) 2006-03-10
EP1587538B1 (en) 2014-04-02
US8926992B2 (en) 2015-01-06
JP2005525415A (ja) 2005-08-25
EP1506008B1 (en) 2009-07-22
CN100579580C (zh) 2010-01-13
RU2005127200A (ru) 2006-06-10
ES2470765T3 (es) 2014-06-24
US20060051378A1 (en) 2006-03-09
WO2003094834A2 (en) 2003-11-20
AU2003233128B2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
BR0310062A (pt) Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
BR0210590A (pt) Solubilização de polissacarìdeo capsular e vacinas de combinação
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
BRPI0612670B8 (pt) composição imunogênica, vacina a compreendendo e kit de vacina para a administração concomitante ou sequencial
BRPI0510104A8 (pt) Imunização contra sorogrupo meningocócico y que usa proteínas
DK1835939T3 (da) Meningokokkonjugatvaccination
WO2007026249A3 (en) Multiple vaccination including serogroup c meningococcus
MX2010004271A (es) Formulaciones de vacuna meningococica.
CR10123A (es) Vacuna.
MA30065B1 (fr) Vaccin
RU2009149359A (ru) Состав вакцин против менингита
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
WO2022101745A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2494758C2 (ru) Нейссериальные вакцинные композиции, содержащие комбинацию антигенов

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]